Enabling Safe & Effective Delivery of Self-Amplifying RNA – Overcoming Formulation & CMC Challenges from Preclinical to Clinical
- Understanding how the unique biology of self-amplifying RNA drives distinct delivery requirements, and why conventional LNP approaches may not directly translate
- Exploring tissue-localized formulation strategies to optimize potency, dose efficiency and clinical performance of saRNA therapeutics and vaccines
- Overview of clinical data and platform insights into CMC readiness, including how to navigate manufacturing complexity and leverage early clinical data to inform scalable delivery approaches